Urgent

Acute kidney transplant rejection

transplant rejection · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Immune-mediated graft injury (T-cell-mediated and/or antibody-mediated) presenting as rising creatinine, often with proteinuria or reduced output. Biopsy-directed treatment with steroids, antithymocyte globulin or antibody-directed therapy is needed to salvage the graft.

Red flags

  • Rapidly rising creatinine with oliguria
  • Graft tenderness, fever or pain
  • Strong/rising donor-specific antibodies
  • Vascular (Banff) rejection on biopsy
  • No response to pulsed steroids (steroid-resistant rejection)

Assessment

Differential diagnosis

  • T-cell-mediated rejection
  • Antibody-mediated rejection
  • Calcineurin inhibitor nephrotoxicity
  • BK virus nephropathy
  • Obstruction/urine leak or vascular complication
  • Dehydration/pre-renal or recurrent GN

Investigations

  • Creatinine/eGFR trend and urinalysis/ACR
  • Tacrolimus/ciclosporin level (exclude toxicity)
  • Donor-specific antibodies (DSA)
  • Transplant Doppler ultrasound (exclude obstruction/vascular cause)
  • BK and CMV viral loads
  • Transplant biopsy with Banff grading (definitive) and C4d staining

Management

  • Investigate any unexplained creatinine rise urgently; exclude pre-renal, obstruction, CNI toxicity and infection first
  • Check CNI levels, DSA and viral loads; arrange Doppler ultrasound
  • Obtain a transplant biopsy to confirm and classify rejection (Banff) before definitive therapy
  • Treat T-cell-mediated rejection with pulsed IV methylprednisolone
  • Use antithymocyte globulin for steroid-resistant or severe (vascular) T-cell-mediated rejection
  • Treat antibody-mediated rejection with plasma exchange plus IVIG, +/- rituximab, per centre protocol
  • Optimise and ensure adequate baseline immunosuppression; address non-adherence
  • Give/continue infection prophylaxis given intensified immunosuppression
  • Monitor graft function response and consider repeat biopsy if no improvement
  • Manage complications of treatment (infection, cytokine reactions with ATG)
  • Plan long-term immunosuppression adjustment and DSA monitoring
  • Prepare for return to dialysis/relisting if the graft is not salvageable

Drugs & doses

Methylprednisolone 250-500 mg IV daily for 3-5 days (T-cell-mediated rejection)
Anti-thymocyte globulin 1.5 mg/kg/day IV for 5-7 days (steroid-resistant/severe rejection)
IVIG 1-2 g/kg total divided, with plasma exchange (antibody-mediated rejection)
Rituximab 375 mg/m2 IV (selected antibody-mediated rejection)
Prophylaxis: co-trimoxazole 480 mg PO daily and valganciclovir 900 mg PO daily (renally dosed) during intensified immunosuppression

Disposition

Admit under transplant nephrology; urgent biopsy and treatment at the transplant centre. Close monitoring; involve histopathology and HLA lab.

Complications & pitfalls

  • Graft loss and return to dialysis
  • Infection from intensified immunosuppression
  • Chronic rejection/transplant glomerulopathy
  • Cytokine-release reactions (ATG)
  • Sensitisation complicating re-transplantation
  • Post-transplant lymphoproliferative disorder

Exam pearls

  • Biopsy before treating — distinguish rejection from CNI toxicity and BK nephropathy
  • Antibody-mediated rejection needs DSA testing and C4d, not just steroids
  • Check adherence and drug levels in every rejection episode
  • Intensified immunosuppression demands reinstated infection prophylaxis
  • Early recognition and treatment is key to graft salvage

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.